FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021528767> ?p ?o ?g. }

• W2021528767 endingPage "274" @default.
• W2021528767 startingPage "1" @default.
• W2021528767 abstract "Background The position of invasive urodynamic testing in the diagnostic pathway for urinary incontinence (UI) is unclear. Systematic reviews have called for further trials evaluating clinical utility, although a preliminary feasibility study was considered appropriate. Objectives To inform the decision whether or not to proceed to a definitive randomised trial of invasive urodynamic testing compared with clinical assessment with non-invasive tests, prior to surgery in women with stress UI (SUI) or stress predominant mixed UI (MUI). Design A mixed-methods study comprising a pragmatic multicentre randomised pilot trial; economic evaluation; survey of clinicians’ views about invasive urodynamic testing; qualitative interviews with clinicians and trial participants. Setting Urogynaecology, female urology and general gynaecology units in Newcastle, Leicester, Swansea, Sheffield, Northumberland, Gateshead and South Tees. Participants Trial recruits were women with SUI or stress predominant MUI who were considering surgery after unsuccessful conservative treatment. Relevant clinicians completed two online surveys. Subsets of survey respondents and trial participants took part in separate qualitative interview studies. Interventions Pilot trial participants were randomised to undergo clinical assessment with non-invasive tests (control arm); or assessment as controls, plus invasive urodynamic testing (intervention arm). Main outcome measures Confirmation that units can identify and recruit eligible women; acceptability of investigation strategies and data collection tools; acquisition of outcome data to determine the sample size for a definitive trial. The proposed primary outcome for the definitive trial was International Consultation on Incontinence Modular Questionnaire (ICIQ) Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) (total score) 6 months after surgery or the start of non-surgical treatment; secondary outcomes included: ICIQ-FLUTS (subscales); ICIQ Urinary Incontinence Short Form; ICIQ Lower Urinary Tract Symptoms Quality of Life; Urogenital Distress Inventory; EuroQol-5D; costs, quality-adjusted life-years (QALYs) and incremental cost per QALY, Short Form 12; 3-day bladder diary. Results Of 284 eligible women, 222 (78%) were recruited; 165/219 (75%) returned questionnaires at baseline and 125/200 (63%) who were sent questionnaires at follow-up. There were few missing data items in returned questionnaires, with individual outcome scales calculable for 81%–94%. Most women underwent surgery; management plans were changed in 19 (19%) participants following invasive urodynamic testing. Participant Costs Questionnaires were returned by 53% 6 months after treatment; complete data to undertake cost–utility analysis were available in 27% (intervention) and 47% (control). While insufficient to recommend changes in practice, the results suggest further research would be valuable. All clinicians responding to the survey had access to invasive urodynamic testing, and most saw it as essential prior to surgery in women with SUI with or without other symptoms; nevertheless, 70% considered the research question underlying INVESTIGATE important and most were willing to randomise patients in a definitive trial. Participants interviewed were positive about the trial and associated documentation; the desire of some women to avoid invasive urodynamic testing contrasted with opinions expressed by clinicians through both survey and interview responses. Conclusions All elements of a definitive trial and economic evaluation were rehearsed; several areas for protocol modification were identified. Such a trial would require to 400–900 participants, depending on the difference in primary outcome sought. Future work A definitive trial of invasive urodynamic testing versus clinical assessment prior to surgery for SUI or stress predominant MUI should be undertaken. Trial registration Current Controlled Trials ISRCTN71327395. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2021528767 created "2016-06-24" @default.
• W2021528767 creator A5000280447 @default.
• W2021528767 creator A5000940073 @default.
• W2021528767 creator A5002415902 @default.
• W2021528767 creator A5008717934 @default.
• W2021528767 creator A5010785292 @default.
• W2021528767 creator A5043689450 @default.
• W2021528767 creator A5046382290 @default.
• W2021528767 creator A5050207691 @default.
• W2021528767 creator A5053885717 @default.
• W2021528767 creator A5057452772 @default.
• W2021528767 creator A5074650917 @default.
• W2021528767 creator A5077979469 @default.
• W2021528767 creator A5080266362 @default.
• W2021528767 date "2015-02-01" @default.
• W2021528767 modified "2023-10-17" @default.
• W2021528767 title "INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): a mixed-methods study to assess the feasibility of a future randomised controlled trial of invasive urodynamic testing prior to surgery for stress urinary incontinence in women" @default.
• W2021528767 cites W1227345485 @default.
• W2021528767 cites W1566155680 @default.
• W2021528767 cites W1591838662 @default.
• W2021528767 cites W1880576053 @default.
• W2021528767 cites W1963669729 @default.
• W2021528767 cites W1964749510 @default.
• W2021528767 cites W1965323461 @default.
• W2021528767 cites W1965742808 @default.
• W2021528767 cites W1968208786 @default.
• W2021528767 cites W1978195975 @default.
• W2021528767 cites W1987668599 @default.
• W2021528767 cites W1992736555 @default.
• W2021528767 cites W2000903474 @default.
• W2021528767 cites W2000966104 @default.
• W2021528767 cites W2002152924 @default.
• W2021528767 cites W2017829997 @default.
• W2021528767 cites W2018638843 @default.
• W2021528767 cites W2023110392 @default.
• W2021528767 cites W2028067695 @default.
• W2021528767 cites W2035275234 @default.
• W2021528767 cites W2036002818 @default.
• W2021528767 cites W2037394449 @default.
• W2021528767 cites W2037988196 @default.
• W2021528767 cites W2049678194 @default.
• W2021528767 cites W2049865475 @default.
• W2021528767 cites W2049919747 @default.
• W2021528767 cites W2050315946 @default.
• W2021528767 cites W2051010801 @default.
• W2021528767 cites W2057686551 @default.
• W2021528767 cites W2060139124 @default.
• W2021528767 cites W2064142319 @default.
• W2021528767 cites W2065254956 @default.
• W2021528767 cites W2067987863 @default.
• W2021528767 cites W2071686284 @default.
• W2021528767 cites W2077746108 @default.
• W2021528767 cites W2078823124 @default.
• W2021528767 cites W2087413951 @default.
• W2021528767 cites W2089818065 @default.
• W2021528767 cites W2093069085 @default.
• W2021528767 cites W2093444438 @default.
• W2021528767 cites W2095578592 @default.
• W2021528767 cites W2096751060 @default.
• W2021528767 cites W2098926972 @default.
• W2021528767 cites W2103312600 @default.
• W2021528767 cites W2106265286 @default.
• W2021528767 cites W2108779815 @default.
• W2021528767 cites W2116506203 @default.
• W2021528767 cites W2118907870 @default.
• W2021528767 cites W2119244052 @default.
• W2021528767 cites W2119767902 @default.
• W2021528767 cites W2121671594 @default.
• W2021528767 cites W2123848671 @default.
• W2021528767 cites W2124660213 @default.
• W2021528767 cites W2127397797 @default.
• W2021528767 cites W2137642497 @default.
• W2021528767 cites W2139118963 @default.
• W2021528767 cites W2143342727 @default.
• W2021528767 cites W2145555293 @default.
• W2021528767 cites W2148912141 @default.
• W2021528767 cites W2150832138 @default.
• W2021528767 cites W2158043437 @default.
• W2021528767 cites W2160685948 @default.
• W2021528767 cites W2162664844 @default.
• W2021528767 cites W2167650633 @default.
• W2021528767 cites W2167843281 @default.
• W2021528767 cites W2171723063 @default.
• W2021528767 cites W2211830044 @default.
• W2021528767 cites W4236805817 @default.
• W2021528767 doi "https://doi.org/10.3310/hta19150" @default.
• W2021528767 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781411" @default.
• W2021528767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25714493" @default.
• W2021528767 hasPublicationYear "2015" @default.
• W2021528767 type Work @default.
• W2021528767 sameAs 2021528767 @default.
• W2021528767 citedByCount "11" @default.
• W2021528767 countsByYear W20215287672014 @default.
• W2021528767 countsByYear W20215287672015 @default.
• W2021528767 countsByYear W20215287672016 @default.
• W2021528767 countsByYear W20215287672018 @default.
• W2021528767 countsByYear W20215287672019 @default.

• next